RAC1 inhibition reverses cisplatin resistance in esophageal squamous cell carcinoma and induces downregulation of glycolytic enzymes
Development of chemoresistance remains a major challenge in treating esophageal squamous cell carcinoma (ESCC) patients despite treatment advances. However, the role of RAC1 in chemoresistance of ESCC and the underlying mechanisms remain largely unknown. In this study, we found that higher levels of...
Main Authors: | Rui‐Jie Zeng, Chun‐Wen Zheng, Jing‐E Gu, Hai‐Xia Zhang, Lei Xie, Li‐Yan Xu, En‐Min Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-09-01
|
Series: | Molecular Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1002/1878-0261.12548 |
Similar Items
-
Antitumor Efficacy and Mechanisms of Lapatinib in Combination with Cisplatin on Esophageal Squamous Cancer Cells
by: DOU Qiaohua, et al.
Published: (2019-09-01) -
Targeting MCL-1 sensitizes human esophageal squamous cell carcinoma cells to cisplatin-induced apoptosis
by: Xinfang Yu, et al.
Published: (2017-06-01) -
Clinical Efficacy of Anlotinib Combined with Paclitaxel and Cisplatin as First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma
by: YANG Xiaoli, et al.
Published: (2021-07-01) -
A study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin for advanced esophageal squamous cell carcinoma with T4 and/or M1 lymph node metastasis or locoregional recurrence
by: Qi Liu, et al.
Published: (2020-04-01) -
Dihydroartemisinin Sensitizes Esophageal Squamous Cell Carcinoma to Cisplatin by Inhibiting Sonic Hedgehog Signaling
by: Wei Cui, et al.
Published: (2020-12-01)